Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Imatinib and the long tail of targeted drug development

New molecular insights occasionally lead to the rapid development of therapeutic agents that improve the outcomes of patients with cancer; however, these breakthroughs can be followed by extensive, empirically driven and often unsuccessful efforts at extending the drug to other indications or combinations. Herein, we describe the clinical development of imatinib, a paradigm of rapid molecularly driven drug development, and advocate for a balanced portrayal of the potential of molecularly targeted therapies for cancer.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Accumulating evidence and research organization (AERO)8 diagram of published clinical trials of imatinib.


  1. TIME. Drugs that fight cancer. TIME,16641,20010528,00.html (2001).

  2. Cohen, M. H. et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res. 8, 935–942 (2002).

    CAS  PubMed  Google Scholar 

  3. FDA. Drugs@FDA: FDA approved drug products. FDA (2018).

  4. Yam, C. et al. A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-β. Invest. New Drugs 36, 1103–1109 (2018).

    Article  CAS  Google Scholar 

  5. Carlisle, B. G. et al. Patient benefit and risk in anticancer drug development: a systematic review of the ixabepilone trial portfolio. medRxiv (2019).

  6. Boyiadzis, M. M. et al. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J. Immunother. Cancer 6, 35 (2018).

    Article  Google Scholar 

  7. Walker, I. & Newell, H. Do molecularly targeted agents in oncology have reduced attrition rates? Nat. Rev. Drug Discov. 8, 15–16 (2008).

    Article  Google Scholar 

  8. Hey, S. P., Heilig, C. M. & Weijer, C. Accumulating Evidence and Research Organization (AERO) model: a new tool for representing, analyzing, and planning a translational research program. Trials 14, 1 (2013).

    Article  Google Scholar 

Download references


The work of J.K. is funded by the Canadian Institutes of Health Research (CIHR; EOG111391). Without in any way implying endorsement of the contents of this article, the authors thank members of STREAM and H. Atkins for helpful consultations.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Jonathan Kimmelman.

Ethics declarations

Competing interests

The authors declare no competing interests.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Carlisle, B.G., Zheng, T. & Kimmelman, J. Imatinib and the long tail of targeted drug development. Nat Rev Clin Oncol 17, 1–3 (2020).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer